Bayer AG (BYR.L) on Monday said the U.S. Food and Drug Administration has granted priority review for Hyrnuo as a first-line treatment for HER2-mutated non-small cell lung cancer.
Hyrnuo was approved in November 2025 for patients with non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations and who had previously received systemic therapy.
The application for first-line use is supported by clinical data from the ongoing Phase I/II SOHO-01 study in patients with locally advanced or metastatic HER2-mutated non-small cell lung cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.